PTC Therapeutics Ownership & Insider Activity

PTC Therapeutics Inc

PTCTNASDAQ

Trade with Public

$61.53

2.293.87%

Ult. Agg.: Oct 20, 7:45 AM

$61.31

2.073.49%

Panoramica Notizie Previsioni utili Eventi Obiettivi di prezzo Dati finanziari SentimentAzionariatoConfronta Opzioni Rapporto azionario

Utili: I risultati di Q3 2026 tra 9 giorni da adesso in gio ott 29th, dopo la chiusura del mercato

PTC Therapeutics Ownership & Insider Activity

PTC Therapeutics (PTCT) institutional and insider ownership, recent insider transactions and ownership breakdown.

Insiders own 2.0% of shares outstanding. Institutional investors hold 76.9%. Over the past 90 days, insiders made 7 sales worth $7.3M.

Shares Outstanding

83.461M

Shares Float

61.570M

Insider Shares Owned

1.666M

Insider % Owned

2.0%

Institutional Shares Held

64.199M

Institutional % Held

76.9%

Ownership Breakdown

Net Insider Activity by Month

Purchases (90d)

Sales (90d)

$7.3M total

Net Activity

Net Selling

Net Value (90d)

-$7.3M

PTC Therapeutics Insider Transactions (Last 6 Months)

Visualizza tutte le transazioni degli insider →

Date	Insider	Title	Type	Shares	Price	Value
Oct 14, 2026	MICHAEL SCHMERTZLER	—	SELL	2.500K	$59.61	$149K
Oct 9, 2026	Elliott Mark Boulding	EXEC. VP AND CLO	SELL-OPTIONS	—	$51.84	$5K
Oct 7, 2026	MICHAEL SCHMERTZLER	—	SELL	2.500K	$63.39	$158K
Oct 5, 2026	Elliott Mark Boulding	EXEC. VP AND CLO	SELL-OPTIONS	—	$51.74	$51K
Sep 30, 2026	PHD MD GLENN STEELE JR	—	SELL-OPTIONS	—	$38.20	$647K
Sep 16, 2026	MICHAEL SCHMERTZLER	—	SELL	20.000K	$67.49	$1.3M
Sep 9, 2026	MICHAEL SCHMERTZLER	—	SELL	20.000K	$67.59	$1.4M
Aug 26, 2026	MICHAEL SCHMERTZLER	—	SELL	25.000K	$72.26	$1.8M
Aug 19, 2026	MICHAEL SCHMERTZLER	—	SELL	25.000K	$72.22	$1.8M
Aug 17, 2026	Elliott Mark Boulding	EXEC. VP AND CLO	SELL-OPTIONS	—	$49.13	$132K
Aug 4, 2026	Matthew Klein	CHIEF EXECUTIVE OFFICER	SELL	10.292K	$68.57	$706K
Jul 14, 2026	Pierre Gravier	CHIEF FINANCIAL OFFICER	SELL	3.494K	$80.35	$281K
Jul 9, 2026	Mary Smith	—	SELL-OPTIONS	—	$66.47	$745K
Jul 9, 2026	Gregory Neil Almstead	CHIEF TECHNICAL OPS OFFICER	SELL-OPTIONS	—	$68.39	$108K
Jul 6, 2026	Elliott Mark Boulding	EXEC. VP AND CLO	SELL-OPTIONS	—	$64.22	$212K
Jul 6, 2026	Gregory Neil Almstead	CHIEF TECHNICAL OPS OFFICER	SELL-OPTIONS	—	$63.19	$2.3M
Jun 26, 2026	Gregory Neil Almstead	CHIEF TECHNICAL OPS OFFICER	SELL-OPTIONS	—	$61.68	$383K
Jun 24, 2026	Gregory Neil Almstead	CHIEF TECHNICAL OPS OFFICER	SELL-OPTIONS	—	$61.94	$1.3M
Jun 22, 2026	Gregory Neil Almstead	CHIEF TECHNICAL OPS OFFICER	SELL-OPTIONS	—	$53.30	$1.3M
Jun 17, 2026	Marie Christine Utter	SVP, CHIEF ACCOUNTING OFFICER	SELL-OPTIONS	—	$50.63	$982K
Jun 17, 2026	Elliott Mark Boulding	EXEC. VP AND CLO	SELL-OPTIONS	60.000	$62.60	$333K
Jun 10, 2026	Eric Pauwels	CHIEF BUSINESS OFFICER	SELL	3.711K	$46.51	$1.3M
May 15, 2026	Elliott Mark Boulding	EXEC. VP AND CLO	SELL-OPTIONS	—	$48.93	$131K
May 13, 2026	Matthew Klein	CHIEF EXECUTIVE OFFICER	SELL	72.000	$72.95	$917K
May 8, 2026	Elliott Mark Boulding	EXEC. VP AND CLO	SELL-OPTIONS	—	$62.76	$115K
Apr 21, 2026	Matthew Klein	CHIEF EXECUTIVE OFFICER	SELL	2.850K	$70.91	$202K

More with Benzinga EdgeGet Access

PTC Therapeutics Inc

PTC Therapeutics Ownership & Insider Activity

PTC Therapeutics Insider Transactions (Last 6 Months)

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO

PTC Therapeutics Ownership & Insider Activity

PTC Therapeutics Insider Transactions (Last 6 Months)

People Also Watch

People Also Watch